MassHealth ended coverage of GLP-1s prescribed solely for weight loss on July 3, 2026 (about 22,000 people). Coverage continues for diabetes and for obesity combined with sleep apnea, metabolic liver disease or cardiovascular disease; under-21s are reviewed case by case.
By Dr. SkinnyVIP · Published October 19, 2026 · Quotes link to the original policy or report
“On Friday, the state's Medicaid administrator, MassHealth, ended coverage of GLP-1s and other medications when they're prescribed solely for weight loss”
“roughly 22,000 people statewide who rely on Medicaid to cover anti-obesity drugs for weight loss alone”
“Our proposed change to GLP-1 coverage for weight loss is a targeted approach to control costs, bring us in line with other states, and protect access to care as much as possible.”
The Globe reported the cut was expected to save about $15 million. Separately, a September report found private insurers covered 112,000 fewer Massachusetts residents' GLP-1 weight-loss drugs this year, after Blue Cross Blue Shield of Massachusetts' 2026 change.
“MassHealth will continue covering the drugs if they're prescribed to treat diabetes, their original use, or other medical conditions, or if they are being used to treat obesity in combination with moderate to severe sleep apnea, metabolic liver disease, or cardiovascular disease to reduce the risk of a heart attack or stroke.”
For members under 21, the Globe reported MassHealth would consider medical necessity case by case.
1. Ask your plan one question in writing. “Is there a continuation-of-therapy or medical-necessity exception for members already on a GLP-1, and what documentation does it need?” Many policies keep an exception for diabetes, cardiovascular risk reduction, sleep apnea or liver disease; a letter from your prescriber may qualify you.
2. Check the two public cash-pay routes for the brand-name drug. LillyDirect sells Zepbound to self-pay patients at published prices by dose ($299 to $699 a month for vials as of October 2026, per our Real-Price Index). If you are on Medicare Part D, the Medicare GLP-1 Bridge offers Wegovy or Zepbound for a $50 copay through December 2027 if you meet its criteria (details).
3. If neither fits, know the compounded option's real number. SkinnyVIP's clinician-prescribed compounded tirzepatide is $695 for a 3-month plan (about $232 a month) or $350 for a single month, the same price at every dose, with no membership, no subscription and no automatic renewal; you pay once per plan and nothing bills again unless you ask. If a licensed clinician does not prescribe, the medication cost is refunded in full. Compounded medications are not FDA-approved products; read how it works and what that means before deciding.
Not when prescribed solely for weight loss, as of July 3, 2026. Per the Boston Globe's reporting, coverage continues for diabetes and for obesity treated together with moderate to severe sleep apnea, metabolic liver disease or cardiovascular disease.
The Boston Globe reported roughly 22,000 people statewide relied on MassHealth to cover anti-obesity drugs for weight loss alone, including about 1,700 young people.
The Globe reported MassHealth will still cover GLP-1s for people under 21 when there is medical necessity, considered case by case. Ask your prescriber to submit that request.
At SkinnyVIP, $695 for 3 months (about $232 a month) or $350 for one month, any dose, with no membership or automatic renewal. Compounded medications are not FDA-approved products; prescription is not guaranteed.
Ask your plan about exceptions, check the brand-name cash routes, then compare. SkinnyVIP: $695 for 3 months (about $232/month) or $350 for one, any dose, nothing renews.
Start your consultationCompounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Compounded tirzepatide is separate from FDA-approved Mounjaro® and Zepbound®. A licensed clinician reviews every request; prescription is not guaranteed. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®). This page is general information about published coverage policies, not insurance, legal or medical advice; confirm details with your plan.